III期黑色素瘤患者的辅助治疗与结局:德国皮肤科肿瘤协作组(DeCOG)多中心真实世界研究结果
这项多中心真实世界随访研究分析了589例III期黑色素瘤患者(232例BRAF突变),接受辅助PD-1抑制剂(PD1;n=479)或靶向治疗(TT;n=110)。中位随访25.7个月,BRAF突变患者中PD1组24个月无复发生发生存率为49%,TT组为67%,PD1组复发风险更高(HR 1.99)。
要点
- PD1组因疾病进展提前停药占28.8%(138/479),TT组因不良事件停药占28.2%(31/110)。
- BRAF突变患者中,PD1组24个月RFS为49%,TT组为67%,PD1组复发风险更高(HR 1.99)。
- PD1组24个月黑色素瘤特异性生存率为87%,TT组为92%。
核心结论
- PD1治疗患者较TT患者复发更多且更早;在BRAF突变患者中,辅助TT可能比PD1更有效地预防早期复发。
- 尽管接受辅助治疗仍复发者的管理具有挑战性,对当前治疗选择反应率低。
研究设计与样本
- 多中心真实世界随访研究,纳入589例III期黑色素瘤患者(232例BRAF突变),接受辅助PD-1抑制剂(PD1;n=479)或靶向治疗(TT;n=110)。
- 中位随访25.7个月。
主要发现
- PD1组因疾病进展提前停药占28.8%(138/479),TT组因不良事件提前停药占28.2%(31/110)。
- BRAF突变患者中,PD1组24个月RFS为49%(95% CI 40.6-59.0%),TT组为67%(95% CI 58-77%)。
- BRAF突变患者中,PD1组较TT组复发风险更高(HR 1.99;95% CI 1.34-2.96;经年龄、性别和肿瘤分期调整的HR为2.21;95% CI 1.48-3.30)。
- 24个月MSS在PD1组为87%(95% CI 81.0-94.1),TT组为92%(95% CI 86.6-97.0)。
- 不可切除疾病后续系统治疗的反应率在PD1组为22%,TT组为16%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials demonstrated significantly improved recurrence-free survival (RFS) of melanoma patients receiving adjuvant treatment. As data from controlled trials are based on selected populations, we investigated adjuvantly treated stage III melanoma patients under real-world conditions. PATIENTS AND METHODS: In a prior multicenter cohort study, stage III-IV melanoma patients were analysed for their choice of adjuvant therapy. In this follow-up study, we examined RFS, overall and melanoma-specific survival (MSS) and response to the subsequent treatment of 589 stage III patients (232 BRAF-mutated) receiving adjuvant PD-1 inhibitors (PD1; n = 479) or targeted therapy (TT; n = 110). RESULTS: The median follow-up of the total cohort was 25.7 months. The main reason for premature discontinuation of adjuvant therapy was disease progression in PD1- (28.8%, n = 138/479) and adverse events in TT-treated patients (28.2%, n = 31/110). Among BRAF-mutated patients, RFS at 24 months was 49% (95% CI 40.6-59.0%) for PD1- and 67% (95% CI 58-77%) for TT-treated patients. The risk of recurrence was higher for BRAF-mutated PD1 than TT (hazard ratio 1.99; 95% CI 1.34-2.96; hazard ratio adjusted for age, sex and tumour stage, 2.21; 95% CI 1.48-3.30). Twenty-four months MSS was 87% (95% CI 81.0-94.1) for PD1 and 92% (95% CI 86.6-97.0) for TT. Response to subsequent systemic treatment for unresectable disease was 22% for all PD1- and 16% for TT-treated patients. CONCLUSIONS: PD1-treated patients had more and earlier recurrences than TT patients. In BRAF-mutated patients, adjuvant TT might prevent early recurrences more effectively than PD1 treatment. Management of recurrence despite adjuvant treatment is challenging, with low response to current therapeutic options.
引用
- Lodde GC, Hassel J, Wulfken LM, et al. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study. Eur J Cancer. 2023. PMID: 37487400. doi:10.1016/j.ejca.2023.112957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。